Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsGDTC +12.50%27 3-Year ROIIC % is 332.12 as of Dec. 2025, which is 91% above its 10-year median of 174.17. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, CytoMed Therapeutics ranks better than 88.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
CytoMed Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 332.12%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for CytoMed Therapeutics's 3-Year ROIIC % or its related term are showing as below:
GDTC's 3-Year ROIIC % is ranked better than 88.5% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs GDTC: 332.12
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
CytoMed Therapeutics 3-Year ROIIC % Related Terms
CytoMed Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GDTC vs LEXX, INAB, TRAW: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, CytoMed Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's 3-Year ROIIC % falls into.
CytoMed Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.287 (Dec. 2025) - -1.374 (Dec. 2022) )
/
( 4.222 (Dec. 2025) - 4.798 (Dec. 2022) )
=
-1.913
/
-0.576
=
332.12%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
CytoMed Therapeutics (GDTC) has a 3-Year ROIIC % of 332.12 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CytoMed Therapeutics and its competitors. This is 91% above median its historical median of 174.17. Over the past decade, CytoMed Therapeutics' 3-Year ROIIC % has ranged from 137.93 to 332.12. According to the industry distribution chart, CytoMed Therapeutics ranks #152 out of 1322 companies in the Biotechnology industry, placing it in the top 11.5%.
Is CytoMed Therapeutics' 3-Year ROIIC % too high?
CytoMed Therapeutics' current 3-Year ROIIC % of 332.12 is 91% above median its 10-year median of 174.17. Over the past 10 years, this metric has ranged from a low of 137.93 to a high of 332.12. Based on the distribution chart, CytoMed Therapeutics ranks #152 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' 3-Year ROIIC % compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #152 out of 1322 companies for 3-Year ROIIC %. This places CytoMed Therapeutics in the top 12% of its industry — outperforming the majority of peers. Historically, CytoMed Therapeutics' own 3-Year ROIIC % has ranged from 137.93 to 332.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current 3-Year ROIIC % is 332.12, which is 91% above median its own 10-year median of 174.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current 3-Year ROIIC % of 332.12. The current 3-Year ROIIC % is 332.12, which is 91% above median its 10-year median of 174.17. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current 3-Year ROIIC % is 332.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score
Get the complete analysis for GDTC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDTC has been successfully added to your 
